Effect of chronic rosiglitazone, metformin and glyburide treatment on β‐cell mass, function and insulin sensitivity in mZDF rats
Authors:
- 18 August 2008
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (9) , 780-790
Abstract
Here we investigate the effect of rosiglitazone (RSG), metformin (MET) and glyburide (GLIB) on plasma glucose levels, β‐cell mass, function and insulin sensitivity in 10‐week‐old diabetic male Zucker diabetic fatty (mZDF) rats using quantitative morphometry and a mathematical model β‐cell mass, insulin and glucose kinetics (βIG). At treatment start, 10‐week‐old diabetic mZDF rats were severely hyperglycaemic and had very low β‐cell function (insulin secretory capacity). RSG treatment significantly lowered plasma glucose levels in 67% of the mZDF rats. MET was effective at lowering plasma glucose levels in 33% of the mZDF rats, while GLIB was completely ineffective at lowering blood glucose levels in 10‐week‐old mZDF rats. RSG treatment prevented the fall in β‐cell mass after 6–8 weeks of treatment accompanied by a significant decrease in β‐cell death while MET treatment had no effect on β‐cell mass. RSG treatment increased insulin sensitivity 10‐fold, increased β‐cell function fivefold and modestly increased β‐cell mass 1.4‐fold. MET treatment increased insulin sensitivity fourfold, with no significant effect on β‐cell function or mass. Although RSG treatment was highly successful in lowering plasma glucose levels, the 33% of mZDF rats that did not respond to the treatment had significantly lower β‐cell function prior to treatment start compared with the responder group. Thus, the low level of β‐cell function at treatment start may explain why none of these agents were completely effective at lowering blood glucose levels in 10‐week‐old diabetic mZDF rats. Nevertheless, these data suggest that the preservation of β‐cell mass and improvement in β‐cell function play a role in the overall beneficial effect of RSG in 10‐week‐old diabetic mZDF rats.Keywords
This publication has 30 references indexed in Scilit:
- Rosiglitazone Protects Against Cyclosporine‐Induced Pancreatic and Renal Injury in RatsAmerican Journal of Transplantation, 2005
- Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human isletsJournal of Diabetes and its Complications, 2005
- Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretionAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- A Model of β -Cell Mass, Insulin, and Glucose Kinetics: Pathways to DiabetesJournal of Theoretical Biology, 2000
- Sustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F CellsBiochemical and Biophysical Research Communications, 2000
- Irreversibility of Nutritionally Induced NIDDM in Psammomys obesus Is Related to β-Cell ApoptosisPancreas, 1999
- Human pancreatic beta-cell deoxyribonucleic acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitroEndocrinology, 1996